Literature DB >> 1612951

Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control.

M S Zaghloul1, H K Awwad, H H Akoush, S Omar, O Soliman, I el Attar.   

Abstract

Two hundred thirty-six patients with T3 bladder cancer who survived radical surgery and proved to have P3a, P3b, or P4a tumors were randomized in two phases into three groups: (a) no further treatment (83 patients); (b) postoperative radiotherapy multiple daily fractionation (MDF), using 3 daily fractions of 1.25 Gy each, with 3 hr between fractions, up to a total dose of 37.5 Gy in 12 days (75 patients); and (c) postoperative radiotherapy conventional fractionation (CF), for a total dose of 50 Gy/5 weeks (78 patients). The tolerance of the patients to postoperative radiotherapy was quite acceptable, with equal acute reactions in MDF and CF groups. The 5-year disease-free survival (DFS) rates amounted to 49 and 44% in MDF and CF postoperative radiotherapy groups, respectively, compared to 25% in the cystectomy-alone group. The 5-year local control rates were 87% and 93% for those treated with multiple daily fractionation and conventional fractionation while it was 50% in the surgery-alone group. The therapeutic benefit of postoperative irradiation was consistent for all tumor types, histological grades, and pathological stages for both the disease-free survival and local control. Patients with nodal metastases demonstrated lower recurrence rates in the postoperative radiotherapy groups, but this was not associated with improved disease-free survival. Multivariate analysis using the Cox Model confirmed these results. The independent prognostic factors affecting both disease-free survival and local control were the addition of postoperative radiotherapy, the nodal status, the pathological stage, and the tumor grade. Late complications of radiotherapy in the skin, small intestine, rectum, and the anastomotic site of the urinary division were lower with MDF than with conventional fractionation.

Entities:  

Mesh:

Year:  1992        PMID: 1612951     DOI: 10.1016/0360-3016(92)90005-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

1.  Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.

Authors:  Mohamed S Zaghloul; John P Christodouleas; Andrew Smith; Ahmed Abdallah; Hany William; Hussein M Khaled; Wei-Ting Hwang; Brian C Baumann
Journal:  JAMA Surg       Date:  2018-01-17       Impact factor: 14.766

Review 2.  Trimodality therapy for bladder cancer: modern management and future directions.

Authors:  Anthony Pham; Leslie K Ballas
Journal:  Curr Opin Urol       Date:  2019-05       Impact factor: 2.309

3.  Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patients.

Authors:  Rania Bakry; Mohamed I El-Sayed; Hesham M Hamza; Khaled H Hassan
Journal:  Oncol Lett       Date:  2015-11-17       Impact factor: 2.967

Review 4.  Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.

Authors:  Rosa Nadal; Andrea B Apolo
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

Review 5.  Radiotherapy with radical cystectomy for bladder cancer: A systematic review and meta-analysis.

Authors:  Kristen Mcalpine; Dean A Fergusson; Rodney H Breau; Luke F Reynolds; Risa Shorr; Scott C Morgan; Libni Eapen; Ilias Cagiannos; Chris Morash; Luke T Lavallée
Journal:  Can Urol Assoc J       Date:  2018-05-28       Impact factor: 1.862

6.  Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy.

Authors:  Behfar Ehdaie; Alexandra Maschino; Shahrokh F Shariat; Jorge Rioja; Robert J Hamilton; William T Lowrance; Stephen A Poon; Hikmat A Al-Ahmadie; Harry W Herr
Journal:  J Urol       Date:  2011-11-16       Impact factor: 7.450

7.  National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013.

Authors:  Zhoobin H Bateni; Shane M Pearce; Daniel Zainfeld; Leslie Ballas; Hooman Djaladat; Anne K Schuckman; Siamak Daneshmand
Journal:  Eur Urol Oncol       Date:  2018-12-19

8.  Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer.

Authors:  Venu Chalasani; Joseph L Chin; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

9.  Pattern of failure in bladder cancer patients treated with radical cystectomy: rationale for adjuvant radiotherapy.

Authors:  Yong Bae Kim; Sung Joon Hong; Seung Cheol Yang; Jae Ho Cho; Young Deuk Choi; Gwi Eon Kim; Koon Ho Rha; Woong Kyu Han; Nam Hoon Cho; Young Taek Oh
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

Review 10.  Radiation therapy in urinary cancer: state of the art and perspective.

Authors:  M Troiano; P Corsa; A Raguso; S Cossa; M Piombino; G Guglielmi; S Parisi
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.